ex-{num} 
exhibit {num} 
cytodyn announces ${num} million registered direct offering 
vancouver , washington , september {num} {num} ( globe newswire ) — cytodyn inc . ( otc . qb : cydy ) , a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus ( hiv ) infection , today announced that it has entered into definitive agreements with healthcare dedicated institutional investors for an offering of {num} shares of common stock , at a price per share of ${num} and warrants to purchase {num} shares of common stock with gross proceeds of approximately ${num} million in a registered direct offering . the warrants have an exercise price of ${num} per share and will expire five years from the date of issuance . the closing of the offering is expected to take place on or about september {num} {num} subject to the satisfaction of customary closing conditions . 
rodman & renshaw , a unit of h . c . wainwright & co . , llc , acted as the exclusive placement agent in connection with this offering . 
net proceeds from the offering are expected to be approximately ${num} million . cytodyn intends to use the net proceeds from the offering to fund clinical trials for its product candidates and for general corporate purposes . 
the securities described above are being offered by cytodyn pursuant to a shelf registration statement ( file no . {num}-{num} ) previously filed with and subsequently declared effective by the securities and exchange commission ( the " sec " ) . a prospectus supplement relating to the offering will be filed with the sec and will be available on the sec's website at http : / / www . sec . gov and following such filing , copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the sec's website at http : / / www . sec . gov , or from h . c . wainwright & co . by e-mailing placements@hcwco . com . 
this press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein . there shall not be any offer , solicitation of an offer to buy , or sale of securities in any state or jurisdiction in which such an offering , solicitation , or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction . 
about cytodyn 
cytodyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of hiv infection . the company has one of the leading monoclonal antibodies under development for hiv infection , pro {num} which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase {num} pro {num} blocks the hiv co-receptor ccr5 on t cells , which prevents viral entry . clinical trial results thus far indicate that pro {num} does not negatively affect the normal immune functions that are mediated by ccr{num} results from seven phase 1 and phase 2 human clinical trials have shown that pro {num} can significantly reduce viral burden in people infected with hiv . a recent phase 2b clinical trial demonstrated that pro {num} can prevent viral escape in patients during several months of interruption from conventional 
drug therapy . cytodyn intends to continue to develop pro {num} as a therapeutic anti-viral agent in persons infected with hiv and to pursue non-hiv indications where ccr5 and its ligand ccl5 may be involved . for more information on the company , please visit www . cytodyn . com . 
about pro {num} 
pro {num} belongs to a new class of hiv / aids therapeutics – viral-entry inhibitors – that are intended to protect healthy cells from viral infection . pro {num} is a humanized igg4 monoclonal antibody directed against ccr{num} a molecular portal that hiv uses to enter t-cells . pro {num} blocks the predominant hiv ( r5 ) subtype entry into t-cells by masking this required co-receptor , ccr{num} importantly , pro {num} does not appear to interfere with the normal function of ccr5 in mediating immune responses . pro {num} does not have agonist activity toward ccr5 but does have antagonist activity to ccl{num} which is a central mediator in inflammatory diseases . pro {num} has been the subject of seven clinical trials , each demonstrating efficacy by significantly reducing or controlling hiv viral load in human test subjects . pro {num} has been designated a " fast track " product candidate by the fda . the pro {num} antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use . 
forward-looking statements 
this press release includes forward-looking statements and forward-looking information within the meaning of united states securities laws , including all statements regarding the completion of the offering , use of proceeds and size of the offering . these statements and information represent cytodyn's intentions , plans , expectations , and beliefs and are subject to risks , uncertainties and other factors , many beyond cytodyn's control . these factors could cause actual results to differ materially from such forward-looking statements or information . the words " believe , " " estimate , " " expect , " " intend , " " attempt , " " anticipate , " " foresee , " " plan , " and similar expressions and variations thereof identify certain of such forward-looking statements or forward-looking information , which speak only as of the date on which they are made . 
cytodyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information , whether as a result of new information , future events or otherwise , except as required by applicable law . readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information . while it is impossible to identify or predict all such matters , these differences may result from , among other things , the inherent uncertainty of the timing and success of and expense associated with research , development , regulatory approval , and commercialization of cytodyn's products and product candidates , including the risks that clinical trials will not commence or proceed as planned ; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials ; future clinical trial data on cytodyn's products and product candidates will be unfavorable ; funding for additional clinical trials may not be available ; cytodyn's products may not receive marketing approval from regulators or , if approved , may fail to gain sufficient market acceptance to justify development and commercialization costs ; competing products currently on the market or in development may reduce the commercial potential of cytodyn's products ; cytodyn , its collaborators or others may identify side effects after the product is on the market ; or efficacy or safety concerns regarding marketed products , whether or not scientifically 
justified , may lead to product recalls , withdrawals of marketing approval , reformulation of the product , additional pre-clinical testing or clinical trials , changes in labeling of the product , the need for additional marketing applications , or other adverse events . 
cytodyn is also subject to additional risks and uncertainties , including risks associated with the actions of its corporate , academic , and other collaborators and government regulatory agencies ; risks from market forces and trends ; potential product liability ; intellectual property litigation ; environmental and other risks ; and risks that current and pending patent protection for its products may be invalid , unenforceable , or challenged or fail to provide adequate market exclusivity . there are also substantial risks arising out of cytodyn's need to raise additional capital to develop its products and satisfy its financial obligations ; the highly regulated nature of its business , including government cost-containment initiatives and restrictions on third-party payments for its products ; the highly competitive nature of its industry ; and other factors set forth in cytodyn's annual report on form {num}-k for the fiscal year ended may {num} {num} and other reports filed with the u . s . securities and exchange commission . 
contacts : 
investors : 
lha 
jody cain 
office : {num}-{num}-{num} 
e-mail : jcain@lhai . com 
media : 
rooneypartners 
marion janic 
office : {num}-{num}-{num} 
email : mjanic@rooneyco . com 
